Latest filing published 24 Apr 2020 for Lexicon Pharmaceuticals, INC., €12k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -56.2%Entry US$3.56 · Close at T+365 US$1.56
- -39.8%Entry US$9.84 · Close at T+365 US$5.92
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Alexander A. Santini: trading record in brief
Alexander A. Santini discloses dealings in Lexicon Pharmaceuticals, Inc. to SEC (Form 4). Between 28 February 2017 and 22 April 2020, the trades on record add up to 19 filings.
No open-market sale appears; the market trades are 3 purchases worth €20k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 6 share grants and 10 option exercises.
A typical purchase (the median) is worth €6,382. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 3 purchases show a median change of +24.4%, with the price up in 100% of them. These figures describe past trades and do not predict future prices.
On 24 April 2020 came the latest disclosure, a share grant for €12k in Lexicon Pharmaceuticals, Inc. The last purchase on record was published on 19 September 2019, which is 2,608 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Alexander A. Santini
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,813 shares@ US$1.9628.3% of flowCommon StockSEC:0001127602-20-014492:1
- 19,893 shares0Common StockSEC:0001127602-20-014492:0
- 12,420 shares@ US$2.7754.6% of flowCommon StockSEC:0001127602-20-008965:4
- 2,353 sharesCommon StockSEC:0001127602-20-008965:0
- 2,593 sharesCommon StockSEC:0001127602-20-008965:1
- 8,464 sharesCommon StockSEC:0001127602-20-008965:2
- 22,853 sharesCommon StockSEC:0001127602-20-008965:3
- 2,500 shares@ US$3.239.2% of flowCommon StockSEC:0001127602-19-028812:0Canonical exit: 17 Dec 2019 (T+90)
- 2,000 shares@ US$3.528.0% of flowCommon StockSEC:0001127602-19-028812:1Canonical exit: 17 Dec 2019 (T+90)
- 2,352 sharesCommon StockSEC:0001127602-19-009264:0
- 2,593 sharesCommon StockSEC:0001127602-19-009264:1
- 8,463 sharesCommon StockSEC:0001127602-19-009264:2
- 4,544 shares@ US$5.5125.7% of flowCommon StockSEC:0001127602-19-009264:3
- 745 shares@ US$9.785.5% of flowCommon StockSEC:0001127602-18-018984:0Canonical exit: 21 Aug 2018 (T+90)
- 2,353 sharesCommon StockSEC:0001127602-18-009731:0
- 2,592 sharesCommon StockSEC:0001127602-18-009731:1
- 1,652 shares@ US$8.5310.1% of flowCommon StockSEC:0001127602-18-009731:2
- 1,093 shares@ US$16.4514.9% of flowCommon StockSEC:0001127602-17-009396:1
- 2,352 sharesCommon StockSEC:0001127602-17-009396:0
19 of 19 declarations